ASX cannabis shares eyeing $63 billion in legal global sales

Global perceptions of cannabis have come a long way since the 1960s…

| More on:
cannabis brownies and joints surrounded by dollar bills

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX cannabis shares put in a mixed performance in the 2021 financial year (FY21).

Of the 9 stocks broadly falling into the 'ASX cannabis share' category, 6 saw their share prices fall while 3 gained in FY21.

Creso Pharma Ltd (ASX: CPH) was the top performer in FY21, gaining 352%.

Cann Group Ltd (ASX: CAN) came in near the bottom of the list, with shares falling 57%.

Unlike stocks producing other commodities – from gold to almonds – the price of marijuana doesn't impact companies involved in medicinal and recreational cannabis production nearly as directly.

There are numerous factors that determine any listed company's share price. These include quality of management, debt levels, market growth outlook, and barriers to entry for any would-be competitors, to name a few.

But you just need to look at how ASX gold shares perform during a time of rising gold prices relative to a time of falling gold prices (as we've experienced recently) to see the price of gold has a strong impact on their share prices.

The march to legalisation

Cannabis, however, is a rather unique commodity, in that it remains illegal across much of the world.

With that in mind, ASX cannabis shares, and indeed pot stocks across the world, tend to do well when the global legal market expands as the stigma of illegality is gradually stripped away.

As you're likely aware, the illicit nature of cannabis has been inexorably changing, led by Uruguay.

Yes, Uruguay.

In 2013 the tiny South American nation became the first on Earth to fully legalise cannabis. Since then, Canada and many states in the US have followed suit, with Mexico debating similar legislation.

A potential $63 billion market by 2025

Online investment platform eToro's market analyst Josh Gilbert points to a forecast by JPMorgan that estimates legal cannabis sales could hit US$45 billion (AU$63 billion) by 2025.

Gilbert told the Motley Fool this "will see most cannabis stocks scrabbling for market share. As cannabis sales increase, the sector is becoming more and more saturated".

While legal recreational use is a growing segment, the medicinal properties of cannabis are helping drive wider global acceptance.

"The plant's contribution to pain relief, cancer treatment and other medical issues has been well researched and documented, and a booming industry has started to grow around it," Gilbert said.

With New York slated to green-light recreational marijuana use in 2022, the global cannabis market is growing like a weed.

A US listed pot stock to consider

Gilbert points to Canopy Growth Corp (NASDAQ: CGC) as an international share that could do well in an expanding legal cannabis market:

The largest cannabis stock by market cap, Canopy Growth, has arguably positioned itself to benefit from the flourishing legalisation of cannabis, by focusing on target countries such as Canada, the US and Germany.

With Canada having fully legalised recreational marijuana alongside its medicinal uses, companies have been turning to infusing food and drinks with THC, the active ingredient that gets users "high". Gilbert said that edibles and beverages accounted for 47% of Canopy Growth's sales in FY21.

He added:

Canopy Growth is in the prime position to benefit from all use of cannabis products, whether that is medicinal or recreational. Its financial position provides an advantage against its peers, thanks to its partnership with Constellation Brands in the US. Constellation Brands owns around 38.6% of Canopy Growth, which has helped grow its beverage business and further enhance its potential for profitability.

Revenues are also continuing to grow, with its FYQ1 earnings in August 2021 demonstrating a 23% increase year-over-year. Despite this, the company's revenues came in short against analyst expectations.

Up 1.2% over the past 12 months, Canopy's share price is down 37% year-to-date. Gilbert says this is an important reminder "that investing in cannabis stocks doesn't come without its risks".

He added: "The industry has also experienced a long run of underperformance, but further legalisation of cannabis globally should be the catalyst for share price growth."

How have these 2 ASX cannabis shares been tracking in FY22?

Now let's get back to the 2 ASX cannabis shares mentioned above.

We know how they performed in FY21, the financial year ending 30 June. So how have they done since the start of FY22?

Creso Pharma, the top performer last financial year, is down by 11% since the opening bell on 1 July.

Cann Group, one of the worst-performing ASX cannabis shares in FY21, is continuing to struggle in the new financial year, with shares down by 24% since 1 July.

These ASX cannabis shares, among others, will certainly be eyeing the potential market growth as more US states, and potentially more nations, move to legalise medicinal and recreational marijuana.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

A man in a horse head mask and suit jumps for joy on a beach.
Cannabis Shares

Could ASX cannabis shares be set for a smoking hot rebound?

ASX cannabis stocks could be set for a strong finish to 2024.

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »